Lunai Bioworks (NASDAQ: LNAI) disclosed several business developments in a shareholder letter from CEO David Weinstein, including a defense contract, academic partnerships, and litigation over alleged market manipulation.

In April 2026, the Sacramento-based biotechnology company secured a multi-year defense collaboration through BioSymetrics to deploy its AI-enabled Augusta platform for chemical threat assessment, which it describes as a revenue-generating commercial engagement with the U.S. government.

The company also announced the formation of the Pathfinder Consortium, a group of institutional partners including Harvard University, Brigham and Women's Hospital, the University of Utah, Purdue University, and the University of Colorado.

In the area of precision neurology, Lunai said it is advancing its Augusta platform for applications in epilepsy, Parkinson's disease, and Alzheimer's disease. The company also noted a partnership with BrainStorm Therapeutics and referenced a $1.85 million Phase I/II STTR grant awarded to BioSymetrics for alcohol use disorder research, supported by the NIH.

In May 2026, Lunai filed a lawsuit in the U.S. District Court for the District of Delaware against unidentified parties alleged to have engaged in naked short selling. The company cited anomalous failing-to-deliver of 29.6 million shares, representing 81.6% of all outstanding shares, and noted that trading volume on March 17, 2026, reached 554 million shares, or 15.3 times the total shares outstanding. The court granted expedited discovery, and the company said it is now in the discovery process.

Weinstein also noted that Lunai has regained compliance with Nasdaq listing requirements. The letter is based on a press release issued by Lunai Bioworks.